{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T22:48:03Z","timestamp":1776984483127,"version":"3.51.4"},"reference-count":40,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2019,4,30]]},"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1136\/ejhpharm-2019-001889","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T21:15:30Z","timestamp":1560460530000},"page":"16-21","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Influence of drug\u2013drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus"],"prefix":"10.1136","volume":"28","author":[{"given":"Luis","family":"Margusino-Frami\u00f1\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purificaci\u00f3n","family":"Cid-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Gim\u00e9nez-Arufe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mondelo-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Fern\u00e1ndez-Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Mena-de-Cea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Mart\u00edn-Herranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngeles","family":"Castro-Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,6,13]]},"reference":[{"key":"2024102217111776000_28.1.16.1","unstructured":"World Health Organization . HepatitisC, 2018. Available: http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c [Accessed 03 Feb 2019]."},{"key":"2024102217111776000_28.1.16.2","first-page":"458","article-title":"New direct-acting antiviral therapies for treatment of chronic hepatitis C virus infection","volume":"11","author":"Ara","year":"2015","journal-title":"Gastroenterol Hepatol"},{"key":"2024102217111776000_28.1.16.3","doi-asserted-by":"crossref","unstructured":"Jakobsen JC , Nielsen EE , Feinberg J , et al . Direct-acting antivirals for chronic hepatitis C (protocol). Cochrane Database of Systematic Reviews, 2017. Available: https:\/\/www.cochrane.org\/CD012143\/LIVER_direct-acting-antivirals-chronic-hepatitis-c [Accessed 03 Feb 2019].","DOI":"10.1002\/14651858.CD012143.pub2"},{"key":"2024102217111776000_28.1.16.4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy585"},{"key":"2024102217111776000_28.1.16.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"2024102217111776000_28.1.16.6","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13095"},{"key":"2024102217111776000_28.1.16.7","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/2050640616678151","article-title":"The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions","volume":"5","author":"Smolders","year":"2017","journal-title":"United European Gastroenterol J"},{"issue":"1 Suppl","key":"2024102217111776000_28.1.16.8","first-page":"102","article-title":"Toxicity and risks from drug-to-drug interactions of new antivirals for chronic hepatitis C","volume":"21","author":"Binda","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2024102217111776000_28.1.16.9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27920"},{"key":"2024102217111776000_28.1.16.10","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000000198"},{"key":"2024102217111776000_28.1.16.11","unstructured":"Ministry of Health, Social Services and Equality . Strategic plan for tackling hepatitis C in the Spanish National Health System. Available: https:\/\/www.mscbs.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/hepatitisC\/PlanEstrategicoHEPATITISC\/docs\/PEAHC_eng.pdf [Accessed 03 Feb 2019]."},{"key":"2024102217111776000_28.1.16.12","first-page":"660","article-title":"Implementation of specialized pharmaceutical care hospital outpatient clinics in a hospital pharmacy department","volume":"41","author":"Margusino-Frami\u00f1\u00e1n","year":"2017","journal-title":"Farm Hosp"},{"key":"2024102217111776000_28.1.16.13","first-page":"313","article-title":"[Debut in diabetic patients with hepatitis C treatment with ledipasvir\/ sofosbuvir (Harvoni\u00ae)]","volume":"41","author":"Vicente-S\u00e1nchez","year":"2017","journal-title":"Farm Hosp"},{"key":"2024102217111776000_28.1.16.14","first-page":"470","article-title":"Relationship between pharmacotherapy complexity and patient satisfaction with treatment for hepatitis C","volume":"41","author":"Robustillo-Cort\u00e9s","year":"2017","journal-title":"Farm Hosp"},{"key":"2024102217111776000_28.1.16.15","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1512"},{"key":"2024102217111776000_28.1.16.16","unstructured":"University of Liverpool. Hep drug interactions. Available: https:\/\/www.hep-druginteractions.org\/ [Accessed 03 Feb 2019]."},{"key":"2024102217111776000_28.1.16.17","unstructured":"Lexicom drug interactions. Available: https:\/\/www.uptodate.com.mergullador.sergas.es\/drug-interactions\/?source=legacy_nav#di-druglist [Accessed 03 Feb 2019]."},{"key":"2024102217111776000_28.1.16.18","unstructured":"IBM Micromedex. Available: http:\/\/www.micromedexsolutions.com\/micromedex2\/librarian [Accessed 03 Feb 2019]."},{"key":"2024102217111776000_28.1.16.19","first-page":"68","article-title":"Intelligent monitoring system for antiviral pharmacotherapy in patients with chronic hepatitis C (SiMON-VC)","volume":"41","author":"Margusino-Frami\u00f1\u00e1n","year":"2017","journal-title":"Farm Hosp"},{"key":"2024102217111776000_28.1.16.20","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H018"},{"key":"2024102217111776000_28.1.16.21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/1060028018766507","article-title":"Incidence of drug interactions identified by clinical pharmacists in veterans initiating treatment for chronic hepatitis C infection","volume":"52","author":"Ottman","year":"2018","journal-title":"Ann Pharmacother"},{"key":"2024102217111776000_28.1.16.22","first-page":"542","article-title":"Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice","volume":"30","author":"Papatheodoridi","year":"2017","journal-title":"Ann Gastroenterol"},{"key":"2024102217111776000_28.1.16.23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01778-15"},{"key":"2024102217111776000_28.1.16.24","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s40262-016-0373-8","article-title":"Drug-drug interactions between the anti-hepatitis C virus 3D regimen of ombitasvir, paritaprevir\/ritonavir, and dasabuvir and eight commonly used medications in healthy volunteers","volume":"55","author":"Polepally","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2024102217111776000_28.1.16.25","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.074518"},{"key":"2024102217111776000_28.1.16.26","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.transproceed.2018.01.006","article-title":"Ombitasvir-paritaprevir-ritonavir therapy in a kidney transplant recipient with chronic hepatitis C virus genotype 1 infection: a case report on the importance of considering drug-drug interactions and monitoring cyclosporine levels","volume":"50","author":"Takeuchi","year":"2018","journal-title":"Transplant Proc"},{"key":"2024102217111776000_28.1.16.27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s11904-015-0277-5","article-title":"Drug interactions of hepatitis C direct-acting antivirals in the HIV-infected person","volume":"12","author":"El-Sherif","year":"2015","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2024102217111776000_28.1.16.28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40121-015-0061-2","article-title":"Drug-drug interactions among hepatitis C virus (HCV) and human immunodeficiency virus (HIV) medications","volume":"4","author":"Kaur","year":"2015","journal-title":"Infect Dis Ther"},{"key":"2024102217111776000_28.1.16.29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02605-15"},{"key":"2024102217111776000_28.1.16.30","first-page":"106","article-title":"Clinically significant drug-drug interactions between hepatitis C virus and HIV treatments","volume":"24","author":"Kiser","year":"2016","journal-title":"Top Antivir Med"},{"key":"2024102217111776000_28.1.16.31","unstructured":"European AIDS Clinical Society . EACS guidelines, 2018. Available: http:\/\/www.eacsociety.org\/files\/2018_guidelines-9.1-english.pdf [Accessed 03 Feb 2019]."},{"key":"2024102217111776000_28.1.16.32","unstructured":"US Department of Health and Human Services . Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Available: https:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv\/0 [Accessed 03 Feb 2019]."},{"key":"2024102217111776000_28.1.16.33","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015576180"},{"issue":"Suppl 1","key":"2024102217111776000_28.1.16.34","first-page":"S22","article-title":"Pharmacokinetics and drug interactions of medications used to treat hepatitis C virus infection in the setting of chronic kidney disease and kidney transplantation","volume":"22 Suppl 1","author":"Ortiz","year":"2018","journal-title":"Hemodial Int"},{"key":"2024102217111776000_28.1.16.35","first-page":"92","article-title":"Hepatitis C virus direct-acting antiviral drug interactions and use in renal and hepatic impairment","volume":"23","author":"Hill","year":"2015","journal-title":"Top Antivir Med"},{"key":"2024102217111776000_28.1.16.36","unstructured":"Flamm S , Reddy KR , Zadeikis N , et al . Efficacy and pharmacokinetics of glecaprevir and pibrentasvir with concurrent use of acid-reducing agents in patients with chronic HCV infection. Clin Gastroenterol Hepatol 2018."},{"key":"2024102217111776000_28.1.16.37","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.28782","article-title":"Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study","volume":"64","author":"Tapper","year":"2016","journal-title":"Hepatology"},{"key":"2024102217111776000_28.1.16.38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172159","article-title":"Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study","volume":"12","author":"Kondili","year":"2017","journal-title":"PLoS One"},{"key":"2024102217111776000_28.1.16.39","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3748\/wjg.v23.i9.1618","article-title":"Optimizing hepatitis C virus treatment through pharmacist interventions: identification and management of drug-drug interactions","volume":"23","author":"Langness","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2024102217111776000_28.1.16.40","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13769"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2019-001889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:13:57Z","timestamp":1729642437000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2019-001889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,13]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,18]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1136\/ejhpharm-2019-001889"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2019-001889","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,13]]}}}